Latest Regulatory News

Jupiter Energy Limited reported steady oil sales revenue of approximately US$1.76 million for Q4 2024, driven entirely by domestic channels, alongside commissioning a key gas utilisation project and launching a $4 million capital raise.

Artrya Limited reports solid progress on its FDA 510(k) application and secures a A$5 million capital raise, positioning itself for imminent commercial rollout in the US healthcare sector.

Skylark Minerals has reshaped its leadership team with seasoned gold industry veterans and agreed to divest its Citronen Zn-Pb Project, positioning the company for renewed growth and exploration success.

Brazilian Rare Earths Limited reports unprecedented ultra-high-grade rare earth intercepts and significant district-scale mineral discoveries at its Monte Alto project, alongside key permitting milestones advancing its mining ambitions.

Global Lithium Resources pauses Definitive Feasibility Study on its flagship Manna Lithium Project due to challenging lithium markets, while advancing strategic acquisitions and exploration in Western Australia.

Neurotech International reports key clinical progress in paediatric neurological disorders, securing FDA orphan drug designation for its Rett Syndrome treatment and advancing pivotal trials for ASD and PANDAS/PANS.

Lykos Metals Limited narrows its Sockovac project tenement while securing an extended exploration permit for Jezero, positioning itself for focused growth in Bosnia and Herzegovina.

Cokal Limited has partnered with Cratus Group to establish an Infrastructure Joint Venture aimed at significantly expanding coal transport capacity and efficiency, supporting a ramp-up in metallurgical coal production at the BBM mine.

Australian Vanadium Limited's flagship project has been officially recognised under Western Australia's Lead Agency Framework, positioning it at the forefront of the state's clean energy and economic diversification agenda.

Rox Resources has completed its $27 million capital raising with the final tranche of shares issued to institutional investors and company directors, signaling strong backing for its growth plans.

PYC Therapeutics reports substantial progress across all four of its drug development programs in Q4 2024, including key regulatory designations and clinical milestones that set the stage for pivotal trials in 2025.

Noronex Limited has lodged applications for two expansive Prospecting Licences in Botswana adjacent to its active Damara Copper Project in Namibia, signaling a strategic push into new, unexplored terrain within the Kalahari Copper Belt.